News & Highlights
Doppel Pharma CDMO delivered the first validation & Commercial batches of Ravidasvir
On March 8th Doppel Pharma CDMO delivered the first validation & Commercial batches of Ravidasvir, to be commercialized in Malaysia for the treatment of Hepatitis C. Hepatitis C is a viral infection that causes liver inflammation, sometimes leading to serious liver damage including cancer. Ravidasvir is an oral NS5A inhibitor discovered, owned and patented by Presidio Pharmaceuticals, USA. It was licensed to Egyptian drug manufacturer [...]
Meet Doppel-Dietopack in Berlin on March 30-31 at Pharma Contract Manufacturing.
Rocco Paracchini, CCO at Doppel-Dietopack, will walk you through our Technological and industrial capabilities as applicable to NCE, OTC, GX and nutraceutical (for humans and pets)
Welcome Sotax CE7
We are very proud to welcome Sotax CE7 Smart flow-through dissolution testing system a.k.a #USP IV apparatus or EP Flow-through cell in our labs! Doppel Farmaceutici R&D Unit consolidates his capability in drug release testing and in-vitro/in-vivo correlation (IVIVC) studies of poorly soluble, modified/extended release and low dose products. Complete flexibility on media volumes and repeatable positioning of virtually all dosage forms such as softgel capsules, semi-solids, [...]
Doppel Farmaceutici annuncia l’acquisizione di Dietopack.
E’ con orgoglio ed immenso piacere che Doppel Farmaceutici annuncia l’acquisizione del 90% di Dietopack, azienda emiliana tra le principali in Italia che sviluppa, produce e confeziona integratori, alimenti a fini medici e dispositivi medici per conto terzi. Con un fatturato di circa 10 milioni di euro e 60 dipendenti in totale, l'azienda di Medolla (MO) presidia l’intero ciclo della catena del valore: dallo [...]
Internationalization of a European CDMO
Doppel is a leading Italian, finished dose contract development and manufacturing organization (CDMO) with aggressive plans for expanding its presence in international markets. Backed by a private equity firm with a strategic outlook, the company has been investing in new capabilities and capacities designed to meet the evolving needs of its customers. Recent U.S. Food and Drug Administration (FDA) approval of solid oral dose manufacturing [...]